Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

Mer­ck KGaA’s BTK in­hibitor has failed to meet the pri­ma­ry end­point in a pair of reg­is­tra­tional tri­als in re­laps­ing mul­ti­ple scle­ro­sis (RMS), a dis­ap­point­ment that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.